ReviewObstetrics and gynecology international2013
The estrogen receptor joins other cancer biomarkers as a predictor of outcome.
Review in Obstetrics and gynecology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- miR-497-5p Decreased Expression Associated with High-Risk Endometrial Cancer.International journal of molecular sciences · 2020Article
- Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer.Journal of Cancer · 2020Article
- GPER modulators: Opportunity Nox on the heels of a class Akt.The Journal of steroid biochemistry and molecular biology · 2018Review
- Bioinformatics Analysis of Estrogen-Responsive Genes.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.Gynecologic oncology · 2016Article
- An immunohistochemical study on the expression of sex steroid receptors, Ki-67 and cytokeratins 7 and 20 in feline endometrial adenocarcinomas.BMC veterinary research · 2015Article
- Menopausal hormone therapy and cancer: changing clinical observations of target site specificity.Steroids · 2014Review
- Mechanisms linking excess adiposity and carcinogenesis promotion.Frontiers in endocrinology · 2014Review
- The analysis of hormonal status and vascular and cell proliferation in endometrioid endometrial adenocarcinomas.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Endometrial cancer, the most common gynecologic malignancy in the United States, is on the rise, and survival is worse today than 40 years ago. In order to improve the outcomes, better biomarkers that direct the choice of therapy are urgently needed. In this review, we explore the estrogen receptor as the most studied biomarker and the best predictor for response for endometrial cancer reported to date.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.